UCH-L1、PRDX1与AIS患者阿替普酶治疗效果的关系OA

Objective To study the relationship between ubiquitin carboxyl terminal hydrolase L1(UCH-L1),peroxiredox protein 1(PRDX1),and the therapeutic effect of ateplase in patients with acute ischemic stroke(AIS).Methods A total of 198 AIS patients admitted to the First Hospital of Jiaxing from June 2020 to June 2022 were selected as the study group,and 100 healthy individuals who underwent physical examinations during the same period were selected as the healthy group.The serum levels of UCH-L1 and PRDX1 were detected using enzyme linked immunosorbent assay(ELISA).AIS patients were all treated with intravenous thrombolysis with ateplase.After 10 days of treatment,the clinical efficacy was evaluated.Clinical data of patients with different therapeutic effects and differences in serum UCH-L1 and PRDX1 levels were compared,and the relationship between UCH-L1,PRDX1 and the therapeutic effect of ateplase was analyzed.Results The UCH-L1 and PRDX1 of patients in the study group were higher than those in the healthy group(P<0.05).The levels of UCH-L1 and PRDX1 in severe AIS patients were higher than those in moderate and mild AIS patients(P<0.05).UCH-L1 and PRDX1 in complete anterior circulation infarction type AIS patients were higher than those in lacunar infarction,posterior circulation infarction,and partial anterior circulation infarction types(P<0.05).After treatment with ateplase,the levels of UCH-L1 and PRDX1 in AIS patients were lower than before treatment,and the worse the treatment effect of ateplase,the higher the levels of UCH-L1 and PRDX1(P<0.05).The combined prediction of UCH-L1 and PRDX1 for the efficacy of ateplase therapy in AIS patients was better than a single prediction(P<0.05).Age,severity of disease,National Institute of Health stroke scale score at admission,UCH-L1,PRDX1 are risk factors that affect the recovery of AIS patients after ateplase treatment(P<0.05).Conclusion The elevated levels of UCH-L1 and PRDX1 in the serum of AIS patients are related to the severity of the disease and stroke classification,and are risk factors affecting the efficacy of ateplase treatment in AIS patients.They can be used for early prediction of the efficacy of ateplase treatment.